Towards a new therapy for lung cancer?

Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related deaths worldwide. Among recent advancements, tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of this disease in patients with oncogenic mutations. However, the emergence of resistance to TKIs limits their long-term effectiveness. Consequently, identifying new therapies is crucial, and one potential solution lies in combining TKIs with thoracic radiotherapy (RT). This approach aims to prolong survival while maintaining a favorable safety profile. This study examines the benefits of this combined strategy.  

Combining TKIs and radiotherapy: efficacy and side effects